COR Stock Recent News

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Cencora, formerly known as AmerisourceBergen, has achieved a 14.97% YoY increase in total revenue, a 25.38% increase in net income, and a 27.84% increase in free cash flow. The company aims to become the underlying healthcare infrastructure for institutions and organizations, expanding its leadership in the healthcare wholesaler and distribution business. Cencora is investing in margin-enhancing businesses, leveraging its infrastructure for cost efficiency, and focusing on strategic M&A and in-house investment to support expanded leadership opportunities.

Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Does Cencora (COR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Cencora Inc said it has learned that data from its information systems had been exfiltrated, some of which may contain personal information, the drug distributor said in a filing on Tuesday.

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.